1. Medtech Insight
  2. >>Business
  3. >>Investor Eye

Exec Chat: 'Wow Factor' Is Important in Medtech Investment, But It’s Not Everything Says Ceros CEO

'There is a Revolution In Medtech And Money On the Sidelines,’ Ceros’ Mark Goldwasser told Medtech Insight in an interview

 
• By Marion Webb

Medtech Insight interviewed the CEO of Ceros Financial Services and its investment banking division, Ceros Capital Markets, about the firm’s considerations for funding early-stage medtechs, and outlook for medtech fundraising, in this uncertain economic climate.

Mark Goldwasser
• Source: Ceros Financial Services

Mark Goldwasser, CEO of New York-based asset management firm Ceros Financial Services, thinks there is a revolution starting in the medtech industry, money on the sidelines, and opportunities to be had in this post-Covid world.

Goldwasser recently talked to Medtech Insight about the company’s investment portfolio and outlook for medtech investment, which has been facing multiple headwinds this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Investor Eye

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 
• By Natasha Barrow

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Investor Eye: Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments

 
• By Barnaby Pickering

Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.

Investor Eye: Medtech Innovator’s Accelerator Is Catching Up With Pharma

 
• By Barnaby Pickering

Each year, Medtech Innovator whittles down a vast number of applicants to a relatively succinct shortlist of companies. Paul Grand, Medtech Innovator’s CEO, spoke to Medtech Insight about this process, as well as some of the broader trends impacting investment in medtech.

More from Business

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

 
• By Shubham Singh

Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.